查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1945841

注意力不足过动症市场－全球产业规模、份额、趋势、机会及预测（依药物类型、通路、地区及竞争格局划分，2021-2031年）

Attention Deficit Hyperactivity Disorder, Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 181 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球注意力不足过动症(ADHD) 市场预计将从 2025 年的 178.2 亿美元成长到 2031 年的 232.5 亿美元，复合年增长率为 4.53%。

该市场涵盖各类药物製剂，包括兴奋剂和非兴奋剂类药物，以及旨在缓解注意力不足、过动和衝动等症状的治疗设备。大众对神经发育障碍的认知不断提高，以及诊断通讯协定的改进（能够更好地识别成人人群中的此类疾病），是推动市场成长的主要因素。此外，医疗基础设施的改善和精神健康服务保险覆盖范围的扩大，也持续推动全球对这些治疗性介入的需求。

市场概览
预测期 2027-2031
市场规模：2025年 178.2亿美元
市场规模：2031年 232.5亿美元
复合年增长率：2026-2031年 4.53%
成长最快的细分市场 网路药房
最大的市场 北美洲

然而，由于长期存在的供应链中断和生产瓶颈，市场扩张面临许多重大障碍。这些物流限制经常导致药品短缺，阻碍病患治疗的连续性。根据美国国家社区药剂师协会 (NCPA) 的一项调查，到 2024 年，94% 的独立药局业主表示将面临 Adderall 或其学名药短缺的问题。这种产品供应的不稳定性严重威胁着产业的信誉，并限制了市场稳定成长的潜力。

市场驱动因素

儿童和成人族群中注意力不足过动症(ADHD) 盛行率和诊断率的上升是全球 ADHD 市场的主要驱动因素。虽然 ADHD 传统上主要在儿童中被发现，但随着临床认识的提高以及围绕神经发育障碍的污名化现象的消除，成人 ADHD 的诊断数量激增，尤其是在以前诊断不足的女性群体中。这种人口结构的变化显着扩大了患者群体，并推动了对治疗性介入的持续需求。根据美国精神医学会 (APA) 2025 年 1 月发布的数据，2020 年至 2023 年间，成人 ADHD 新诊断病例增加了 15%。此外，美国缉毒局 (DEA) 2024 年 11 月的一份报告预测，2023 年美国兴奋剂处方量将达到 8,080 万张，这反映了市场需求的巨大规模。

同时，远距精神病学和数位健康解决方案的普及彻底改变了患者获得过动症治疗的途径，成为市场成长的关键驱动力。远端系统管理平台消除了地理和物流障碍，实现了持续监测和药物管理，这对患者坚持治疗方案至关重要。这种数位转型在应对新患者激增的问题上极为有效，这些患者可能面临长时间的专家面诊预约等待。根据美国疾病管制与预防中心 (CDC) 2024 年 10 月发布的报告，约 46% 的过动症成年患者表示曾使用远端医疗服务，证实了虚拟医疗模式在当前医疗保健环境中的重要作用。

市场挑战

长期存在的供应链中断和生产瓶颈是目前限制全球注意力不足过动症（ADHD）药物市场成长的主要因素。这些物流方面的不稳定性导致製药公司无法满足不断增长的诊断率所带来的需求。当生产无法跟上消费者需求时，由此造成的药品短缺会导致即时的收入损失，并阻碍患者坚持处方治疗方案。产品供应的不确定性削弱了现有治疗方法的商业性稳定性，造成市场波动，并阻碍了产品的持续推广。

这些药品短缺对製药业的影响显而易见，并直接阻碍了市场的稳定发展。根据美国卫生系统药剂师协会统计，2024年第一季出现了创纪录的323种药品短缺，其中大部分是用于治疗注意力不足过动症（ADHD）的兴奋剂。这些大范围的供应链中断迫使医疗机构发行，并推迟治疗的开始时间。这种不确定的环境限制了市场持续扩张的潜力，并对相关人员的长期财务前景产生了负面影响。

市场趋势

作为战略研发转型的一部分，新型非兴奋剂药物正在重塑市场格局。研发重点在于开发能够避免二类管制兴奋剂滥用风险和监管复杂性的製剂。製药公司正加大对具有独特作用机制的非管制药物的投资，以确保在兴奋剂短缺期间治疗的连续性。新核准的非兴奋剂药物迅速占领市场，满足了寻求可靠长期治疗方案且不受生产配额限制的患者的需求，这就是该转型的有力佐证。 Supernus Pharmaceuticals 于 2025 年 2 月宣布，其非兴奋剂药物 Qelbree 的 2024 年全年净销售额将成长 72%，达到 2.413 亿美元，这进一步印证了人们对这类替代治疗方法的日益青睐。

同时，人工智慧 (AI) 和机器学习在诊断流程中的应用，正在克服以往主观症状报告的局限性，并建立新的临床客观性标准。透过分析复杂的行为数据和运动模式，这些计算工具能够为临床医生提供精准的生物标记物，从而减少诊断的不确定性，尤其是在症状往往较为隐匿的成年人群体中。这项技术进步显着提高了初步评估的准确性，并简化了采取适当干预措施的路径。 Qbtech 公司于 2025 年 8 月发布的一项研究表明，在英国(NHS) 中应用混合机器学习演算法，在识别成人注意力不足过动症 (ADHD) 方面实现了 93.61% 的诊断准确率，凸显了人工智慧驱动的精准医疗的巨大潜力。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球注意力不足过动症（ADHD）市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 依药物类型（兴奋剂、非兴奋剂）
    • 按分销管道（零售药局、医院药局、网路药局）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

6. 北美注意力不足过动症（ADHD）市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国家分析
    • 我们
    • 加拿大
    • 墨西哥

7. 欧洲注意力不足过动症(ADHD) 市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国家分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

8. 亚太地区注意力不足过动症（ADHD）市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

9. 中东和非洲注意力不足过动症（ADHD）市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东和非洲：国家分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

10. 南美洲注意力不足过动症（ADHD）市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国家分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 司机
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 最新进展

第十三章 全球注意力不足过动症（ADHD）市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的可能性
  • 供应商电力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Supernus Pharmaceuticals, Inc.
  • Pfizer Inc
  • Novartis AG
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Hisamitsu Pharmaceutical Co., Inc.
  • Chongqing Fujin Biology Medical Company
  • Purdue Pharma LP
  • Mallinckrodt Pharmaceuticals

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 19777

The Global Attention Deficit Hyperactivity Disorder (ADHD) Market is projected to expand from USD 17.82 Billion in 2025 to USD 23.25 Billion by 2031, registering a CAGR of 4.53%. This market encompasses pharmaceutical formulations, including both stimulants and non-stimulants, alongside therapeutic devices designed to mitigate symptoms such as inattention, hyperactivity, and impulsivity. Growth is propelled by increasing public acknowledgment of neurodevelopmental conditions and refined diagnostic protocols that better identify adult populations. Furthermore, improved healthcare infrastructure and expanded insurance coverage for mental health services continue to actively support the global demand for these therapeutic interventions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 17.82 Billion
Market Size 2031USD 23.25 Billion
CAGR 2026-20314.53%
Fastest Growing SegmentOnline Pharmacies
Largest MarketNorth America

Nevertheless, market expansion faces substantial obstacles due to chronic supply chain disruptions and manufacturing bottlenecks. These logistical constraints frequently result in medication scarcities that hamper consistent patient access to treatment. According to the National Community Pharmacists Association, 94 percent of independent pharmacy owners reported experiencing shortages of Adderall or its generic equivalents in 2024. Such instability in product availability poses a critical challenge to industry reliability and limits the potential for steady market growth.

Market Driver

The rising prevalence and diagnosis rates among pediatric and adult populations represent a primary catalyst for the Global Attention Deficit Hyperactivity Disorder (ADHD) Market. While ADHD has historically been identified primarily in children, increased clinical understanding and the destigmatization of neurodevelopmental disorders have led to a surge in adult identifications, particularly among women who were previously underdiagnosed. This demographic shift is significantly expanding the patient pool and driving sustained demand for therapeutic interventions. According to the American Psychiatric Association in January 2025, new ADHD diagnoses among adults increased by 15 percent between 2020 and 2023, while the U.S. Drug Enforcement Administration noted in November 2024 that the projected number of stimulant prescriptions dispensed in the United States reached 80.8 million in 2023, reflecting the substantial scale of market demand.

Concurrently, the proliferation of telepsychiatry and digital health solutions is revolutionizing patient access to ADHD care, acting as a critical driver for market growth. Remote management platforms have dismantled geographical and logistical barriers, allowing for more consistent monitoring and medication management, which is essential for adherence to treatment regimens. This digital shift has been instrumental in accommodating the influx of new patients who might otherwise face long wait times for in-person specialists. According to the Centers for Disease Control and Prevention in October 2024, nearly 46 percent of adults with ADHD reported having utilized telehealth services for their condition, underscoring the pivotal role of virtual care models in the current healthcare landscape.

Market Challenge

Chronic supply chain disruptions and manufacturing bottlenecks currently act as a primary restraint on the growth of the Global Attention Deficit Hyperactivity Disorder Market. These logistical inconsistencies result in the inability of pharmaceutical producers to meet the rising demand driven by increased diagnosis rates. When production fails to align with consumption requirements, the resulting medication scarcity leads to immediate revenue losses and disrupts patient adherence to prescribed therapeutic regimens. This unreliability in product availability compromises the commercial stability of established treatments and creates market volatility that discourages consistent product utilization.

The impact of these shortages is quantitatively significant within the pharmaceutical sector and directly impedes steady market progress. According to the American Society of Health-System Pharmacists, the industry faced an all-time high of 323 active drug shortages during the first quarter of 2024, a figure that heavily comprised central nervous system stimulants used for ADHD management. Such extensive gaps in the supply chain force healthcare providers to ration care or delay treatment initiation. This environment of uncertainty limits the potential for sustained market expansion and negatively affects the long-term financial outlook for stakeholders.

Market Trends

A strategic R&D shift towards novel non-stimulant pharmacotherapies is reshaping the market, prioritizing formulations that circumvent the abuse risks and regulatory complexities associated with Schedule II stimulants. Pharmaceutical developers are increasingly investing in non-controlled substances with unique mechanisms of action to ensure continuity of care during periods of stimulant scarcity. This pivot is evidenced by the rapid commercial uptake of recently approved non-stimulant options among patients seeking reliable, long-term management solutions that remain unaffected by production quotas. According to Supernus Pharmaceuticals in February 2025, the full-year 2024 net sales for its non-stimulant treatment Qelbree surged by 72 percent to reach $241.3 million, underscoring the growing preference for these alternative therapeutic modalities.

Concurrently, the integration of artificial intelligence and machine learning in diagnostic workflows is establishing new standards for clinical objectivity, addressing the historical limitations of subjective symptom reporting. By analyzing complex behavioral data and motor activity patterns, these computational tools provide clinicians with precise biomarkers that reduce diagnostic ambiguity, particularly in adult populations where symptom presentation is often subtle. This technological evolution is significantly improving the accuracy of initial assessments and streamlining the pathway to appropriate intervention. According to Qbtech in August 2025, a study implementing hybrid machine learning algorithms within the National Health Service framework demonstrated a diagnostic accuracy of 93.61 percent for identifying adult ADHD, highlighting the transformative potential of AI-driven precision medicine.

Key Market Players

  • Supernus Pharmaceuticals, Inc.
  • Pfizer Inc
  • Novartis AG
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Hisamitsu Pharmaceutical Co., Inc.
  • Chongqing Fujin Biology Medical Company
  • Purdue Pharma LP
  • Mallinckrodt Pharmaceuticals

Report Scope

In this report, the Global Attention Deficit Hyperactivity Disorder (ADHD) Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Attention Deficit Hyperactivity Disorder (ADHD) Market, By Drug Type

  • Stimulant
  • Non-stimulant

Attention Deficit Hyperactivity Disorder (ADHD) Market, By Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacies
  • online Pharmacies

Attention Deficit Hyperactivity Disorder (ADHD) Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Attention Deficit Hyperactivity Disorder (ADHD) Market.

Available Customizations:

Global Attention Deficit Hyperactivity Disorder (ADHD) Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Type (Stimulant, Non-stimulant)
    • 5.2.2. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, online Pharmacies)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Type
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Type
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. Canada Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Type
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Mexico Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Type
        • 6.3.3.2.2. By Distribution Channel

7. Europe Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. France Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. United Kingdom Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Italy Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Type
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. Spain Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Type
        • 7.3.5.2.2. By Distribution Channel

8. Asia Pacific Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. India Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. Japan Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By Distribution Channel
    • 8.3.4. South Korea Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Type
        • 8.3.4.2.2. By Distribution Channel
    • 8.3.5. Australia Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Type
        • 8.3.5.2.2. By Distribution Channel

9. Middle East & Africa Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Type
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. UAE Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Type
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. South Africa Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Type
        • 9.3.3.2.2. By Distribution Channel

10. South America Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Type
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Type
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Colombia Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Type
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. Argentina Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Type
        • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Attention Deficit Hyperactivity Disorder (ADHD) Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Supernus Pharmaceuticals, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Pfizer Inc
  • 15.3. Novartis AG
  • 15.4. Eli Lilly and Company
  • 15.5. GlaxoSmithKline PLC
  • 15.6. Johnson & Johnson
  • 15.7. Hisamitsu Pharmaceutical Co., Inc.
  • 15.8. Chongqing Fujin Biology Medical Company
  • 15.9. Purdue Pharma LP
  • 15.10. Mallinckrodt Pharmaceuticals

16. Strategic Recommendations

17. About Us & Disclaimer